(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 70.99% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Insmed's revenue in 2025 is $381,030,000.On average, 7 Wall Street analysts forecast INSM's revenue for 2025 to be $84,316,114,513, with the lowest INSM revenue forecast at $81,676,557,241, and the highest INSM revenue forecast at $86,302,885,885. On average, 7 Wall Street analysts forecast INSM's revenue for 2026 to be $180,224,642,919, with the lowest INSM revenue forecast at $154,084,611,107, and the highest INSM revenue forecast at $208,312,286,235.
In 2027, INSM is forecast to generate $363,458,038,708 in revenue, with the lowest revenue forecast at $329,168,747,203 and the highest revenue forecast at $424,383,690,590.